School of Medicine
Showing 1,161-1,180 of 1,552 Results
-
Michael J Rosen, MD, MSCI
Stanford University Endowed Professor for Pediatric IBD and Celiac Disease
BioDr. Rosen is a pediatric gastroenterologist and physician scientist who has been devoted to advancing inflammatory bowel disease (IBD) research and care for 25 years. He is the inaugural Stanford University Endowed Professor for Pediatric IBD and Celiac Disease. He is also Director of the Stanford Medicine Children’s Health Center for IBD and Celiac Disease, which has achieved nationally leading clinical outcomes under his direction. Dr. Rosen’s research expertise crosses mucosal immunology and epithelial biology and clinical and translational investigation. His NIH-funded laboratory has demonstrated the protective role for type 2 cytokines in chronic intestinal inflammation and advanced intestinal organoids as a model to study IBD. His clinical research has demonstrated how proactive therapeutic drug monitoring can be incorporated into clinical practice to optimize ant-TNF therapy treatment response. Dr. Rosen led the multicenter ARCH Study, which demonstrated the importance of intensified anti-TNF drug dosing in pediatric acute severe ulcerative colitis. Presently, he is co-principal investigator for the Crohn's & Colitis Foundation’s Cohort for Pediatric Translational and Clinical Research in IBD (CAPTURE IBD) which will advance precision medicine for children with IBD.
After graduating from Duke University, Dr. Rosen attended Harvard Medical School, followed by pediatrics residency at Boston Children’s Hospital and Boston Medical Center. He pursued his pediatric gastroenterology fellowship at Vanderbilt University Medical Center, where he received a Master of Science in Clinical Investigation. He started his faculty career at Vanderbilt and then moved to Cincinnati Children’s Hospital and the University of Cincinnati College of Medicine. There he rose to Medical Director of the Schubert Martin IBD Center and Associate Director for Faculty Development in the Gastroenterology division before moving to Stanford in 2021. Dr. Rosen serves on the editorial board for Inflammatory Bowel Diseases and the National Scientific Advisory Committee for the Crohn’s & Colitis Foundation. Outside of work, Dr. Rosen enjoys spending time with his wife and two children at their activities, watching movies, downhill skiing, and getting outside. -
David Rosenthal
Professor of Pediatrics (Pediatric Cardiology)
Current Research and Scholarly InterestsResearch interests include the study of Heart Failure, Cardiomyopathy and ventricular dysfunction in children, from a clinical perspective. Investigations include clinical trials of medications, cardiac resynchronization, and mechanical circulatory support.
-
Charlene Larson Rotandi
Associate Director of Fellowship Education, Pediatrics
Current Role at StanfordAssociate Director of Fellowship Education, Department of Pediatrics
Leads initiatives that support the development, administration, and continuous improvement of the 26 subspecialty programs in the Department of Pediatrics. My work focuses on curriculum development and assessment, program accreditation, faculty and program coordinator development, and enhancing the educational experience for our 130+ trainees. I collaborate closely with program leadership and the Graduate Medical Education office to ensure compliance with accreditation standards while advancing innovative approaches to training, mentorship, and professional development. Through my work, I aim to strengthen our learning community by supporting our educational leaders and fostering a collaborative learning environment that promotes trainee success and well-being. -
Stephen J. Roth
Professor of Pediatrics (Cardiology), Emeritus
Current Research and Scholarly InterestsRandomized Therapeutic Trials in Pediatric Heart Disease, NIH/U01 GrantNo. HL68285 2001-2006.
Heparin and the Reduction of Thrombosis (HART) Study. Pediatric Health Research Fund Award, Stanford Univ Sch of Medicine, 2005-2006.
A Pilot Trial fo B-type Natriuretic Peptide for Promotion of Urine Output in Diuretic-Resistant Infants Following Cardiovascular Surgery.Pediatric Health Research Fund Award, Stanford Univ Sch of Medicine, 2005-2006. -
Christopher John Russell
Associate Professor of Pediatrics (Hospital Medicine)
BioDr. Russell is an Associate Professor of Pediatrics in the Division of Pediatric Hospital Medicine and a board-certified academic pediatric hospitalist at Lucile Packard Children’s Hospital. His clinical responsibilities include caring for children hospitalized for a variety of illnesses. His research focuses on developing evidence-based care for hospitalized children with medical complexity, including acute respiratory infections (such as pneumonia and bacterial tracheitis). His research efforts have been recognized through receipt of the University of Southern California’s Clinical and Translational Science Institute’s KL2 Mentored Research Career Development Award (2014-16), the Academic Pediatric Association’s Young Investigator Award (2015-16), the NIH Loan Repayment Program (2017-2021) and a large grant from the Gerber Foundation (2020-2022). In August 2021, he received a five-year R01 award from the Agency for Healthcare Research and Quality to study bacterial respiratory infections in children with tracheostomy. Outside of his clinical and research responsibilities, Dr. Russell focuses on research mentorship of medical students, pediatric residents, and pediatric hospital medicine fellows as well as improving representation of underrepresented minorities in medicine throughout the continuum of physician training. Dr. Russell completed a term as the chair of the Academic Pediatric Association’s Membership, Diversity, and Inclusion Committee (2022-2025) and is on the Executive Committee for the Pediatric Research in Inpatient Settings research network. Dr. Russell is active in the AAP and currently serves as an Associate Editor for the journal Hospital Pediatrics.
-
Katherine Jane Ryan
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
Clinical Assistant Professor (By courtesy), Adult NeurologyCurrent Research and Scholarly InterestsDr. Katherine “Katie” Ryan is a pediatric neuro-oncologist whose research focuses on developing and translating cellular immunotherapies for children with malignant brain tumors. She leads the first-in-human trial of GPC2-directed CAR T cells for CNS Embryonal Tumors. As a member of Stanford Children’s world-renowned pediatric brain tumor team, she diagnoses and treats children with CNS tumors while advancing innovative trial design, intracerebroventricular delivery, and correlative science.
-
Raya Saab
Lindhard Family Professor of Pediatric Cancer Biology
BioI am a pediatric oncologist, and I primarily treat children who are diagnosed with soft tissue sarcomas including rhabdomyosarcoma, and children diagnosed with the eye tumor retinoblastoma, as well as children with other solid tumors.
I have two very different areas of primary research interest, both of which I pursue with passion. One focuses on global oncology, including clinical and research resource capacity building towards effective treatment and improving outcomes of children with cancer worldwide. I work with collaborators across the globe towards a common goal of improving access to diagnostic and clinical care, training of multidisciplinary teams, and building clinical resources and research capacity to develop context-informed approaches to improving cancer care and achieving better outcomes for children diagnosed with cancer irrespective of where they happen to live.
My parallel research interest, which is the focus of my laboratory, is understanding oncogenic signaling in pediatric soft tissue sarcomas, in an effort to clarify the driving biology and determinants of metastatic disease, to uncover novel targets for more effective treatment. We use preclinical in vitro and in vivo models, including murine and human cell lines, and mouse models of cancer. We have recently uncovered a paracrine role for rhabdomyosarcoma-secreted exosomes in impacting biology of stromal cells. Rhabdomyosarcoma-derived exosomes carry specific miRNA cargo that imparts an invasive and migratory phenotype on normal recipient fibroblasts, and proteomic analysis revealed specific and unique pathways relevant to the two different molecular rhabdomyosarcoma subtypes that are driven by distinct oncogenic pathways. We identified that the driver oncogene in fusion-positive rhabdomyosarcoma, PAX3-FOXO1, modulates exosome cargo to promote invasion, migration, and angiogenic properties, and identified specific microRNA and protein cargo acting as effectors of PAX3-FOXO1 exosome-mediated signaling, including modulation of oxidative stress response and cell survival signaling. Our ongoing work is focused on interrogating specific paracrine signaling pathways and molecular mechanisms of metastatic disease progression in rhabdomyosarcoma, for potential therapeutic targeting.
